We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+24.49%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
+$415M
Cap. Flow
+$332K
Cap. Flow %
0.01%
Top 10 Hldgs %
37.9%
Holding
228
New
11
Increased
45
Reduced
33
Closed
6

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$17M
2
UNH icon
UnitedHealth
UNH
+$15.3M
3
CVS icon
CVS Health
CVS
+$14M
4
MRNA icon
Moderna
MRNA
+$13.1M
5
EXEL icon
Exelixis
EXEL
+$9.71M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$29.8M
2
AGN
Allergan plc
AGN
+$28M
3
GILD icon
Gilead Sciences
GILD
+$23.5M
4
ILMN icon
Illumina
ILMN
+$16.8M
5
CI icon
Cigna
CI
+$11.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Real Estate 2.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DHC
176
Diversified Healthcare Trust
DHC
$2.15B
$1.58M 0.06%
357,720
– –
MDGL icon
177
Madrigal Pharmaceuticals
MDGL
$10.8B
$1.51M 0.06%
13,340
– –
ADUS icon
178
Addus HomeCare
ADUS
$2.16B
$1.48M 0.06%
+15,969
New +$1.38M
AUPH icon
179
Aurinia Pharmaceuticals
AUPH
$1.91B
$1.48M 0.06%
90,788
– –
DNTH icon
180
Dianthus Therapeutics
DNTH
$5.84B
$1.45M 0.06%
12,027
+10,980
+1,049% +$1.55M
ASRT
181
DELISTED
Assertio
ASRT
$1.41M 0.05%
+27,372
New +$1.41M
TCDA
182
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.38M 0.05%
+50,370
New +$1.37M
SGMO
183
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.34M 0.05%
149,835
– –
WVE icon
184
Wave Life Sciences
WVE
$1.09B
$1.33M 0.05%
128,146
– –
LKFT
185
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
$1.29M 0.05%
6,543
– –
BBIO icon
186
BridgeBio Pharma
BBIO
$15.7B
$1.28M 0.05%
39,228
– –
KOD icon
187
Kodiak Sciences
KOD
$2.6B
$1.25M 0.05%
23,153
– –
VRNA
188
DELISTED
Verona Pharma
VRNA
$1.18M 0.05%
253,179
– –
NTLA icon
189
Intellia Therapeutics
NTLA
$1.49B
$1.16M 0.04%
55,050
– –
ACIU icon
190
AC Immune
ACIU
$223M
$1.16M 0.04%
171,813
– –
XLV icon
191
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
$1.01M 0.04%
10,055
– –
AXNX
192
DELISTED
Axonics, Inc. Common Stock
AXNX
$987K 0.04%
28,100
– –
AERI
193
DELISTED
Aerie Pharmaceuticals
AERI
$984K 0.04%
66,688
– –
EIDX
194
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$953K 0.04%
20,000
– –
YARW
195
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
$937K 0.04%
150
+101
+206% +$684K
RUBY
196
DELISTED
Rubius Therapeutics, Inc
RUBY
$933K 0.04%
155,982
– –
SNR
197
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$928K 0.04%
256,398
– –
UHT
198
Universal Health Realty Income Trust
UHT
$603M
$895K 0.03%
11,258
– –
GRFS
199
Grifois
GRFS
$5.36B
$864K 0.03%
47,373
– –
MIST icon
200
Milestone Pharmaceuticals
MIST
$138M
$806K 0.03%
213,310
– –
6 7
8
9 10

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, Tekla Capital Management held 228 positions worth $2.63B, up 19% from $2.21B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Tekla Capital Management's Q2 2020 filing shows 11 new, 45 increased, 33 reduced and 6 closed positions. Its largest new stake was Molina Healthcare: 27,536 shares worth $4.9M. The largest sale was Biogen, an estimated $29.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q2 2020 buy was Molina Healthcare: 27,536 shares worth $4.9M.
  • Tekla Capital Management added most to AbbVie in Q2 2020, an estimated $17M increase.
  • Tekla Capital Management's biggest Q2 2020 reduction was Biogen, cutting an estimated $29.8M.
  • Tekla Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $28M.
  • Tekla Capital Management's ten largest holdings make up 38% of its $2.63B portfolio in Q2 2020.
  • Tekla Capital Management opened 11 new positions and closed 6 in Q2 2020.
  • Tekla Capital Management's portfolio value rose 19% quarter-over-quarter to $2.63B.

Based on Tekla Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.